«Hilal Ventures», the institutional venture capital platform of Hilal, announced its participation in the Series A funding round for biotechnology company «Think BioScience», which is developing innovative solutions to address drug targets long considered among the most challenging in drug discovery and development. The new financing of $55 million, which exceeded its target, was led by «Regeneron Ventures», «Innovation Endeavors», and «Janus Henderson Investors». The round also saw participation from «TA Associates», «Hilal Ventures», «MPX Capital», «Wai Kai BioVentures», alongside existing investors «AV8 Ventures», «CU Innovations», and «BevGold Ventures». «Think BioScience» relies on synthetic biology techniques to detect precise positions on proteins that were previously undetectable, including new binding pockets, enabling pharmaceutical chemists to design small-molecule drugs to target proteins that have remained out of reach for drug development for years. This investment in «Think BioScience» reflects Hilal Ventures' focus on supporting visionary entrepreneurs, R&D-driven companies with asset-light and rapidly scalable models across sectors like «deep tech» and «biotech». The company's lead program on Noonan syndrome highlights the platform's significant potential in areas where no approved treatments exist today. The lead program focuses on genetic mutations that cause Noonan syndrome, a genetic condition affecting about one in 2,500 live births, and is associated with serious complications in the heart and lymphatic system, as well as short stature, cognitive disorders, and chronic pain.
